VAXART INC. - COMMON STOCK

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

05 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

24 Feb 2025 09:51:01 By NetDania Notify

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

28 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

14 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

13 Jan 2025 19:55:00 By Nasdaq GlobeNewswire

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

02 Dec 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

13 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

07 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

24 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

30 Sep 2024 16:12:22 By Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

08 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

02 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update

17 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

17 Jun 2024 15:51:57 By NetDania Notify

Vaxart Announces $40 Million Underwritten Offering of Common Stock

13 Jun 2024 19:07:26 By Nasdaq GlobeNewswire